Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Total Liabilities (2016 - 2025)

Haemonetics has reported Total Liabilities over the past 16 years, most recently at $1.6 billion for Q4 2025.

  • Quarterly results put Total Liabilities at $1.6 billion for Q4 2025, down 2.77% from a year ago — trailing twelve months through Dec 2025 was $1.6 billion (down 2.77% YoY), and the annual figure for FY2025 was $1.6 billion, up 31.93%.
  • Total Liabilities for Q4 2025 was $1.6 billion at Haemonetics, down from $1.6 billion in the prior quarter.
  • Over the last five years, Total Liabilities for HAE hit a ceiling of $1.6 billion in Q3 2024 and a floor of $1.1 billion in Q3 2022.
  • Median Total Liabilities over the past 5 years was $1.1 billion (2022), compared with a mean of $1.3 billion.
  • Peak annual rise in Total Liabilities hit 83.77% in 2022, while the deepest fall reached 6.0% in 2022.
  • Haemonetics' Total Liabilities stood at $1.1 billion in 2021, then decreased by 0.08% to $1.1 billion in 2022, then rose by 14.07% to $1.3 billion in 2023, then rose by 29.22% to $1.6 billion in 2024, then dropped by 2.77% to $1.6 billion in 2025.
  • The last three reported values for Total Liabilities were $1.6 billion (Q4 2025), $1.6 billion (Q3 2025), and $1.6 billion (Q2 2025) per Business Quant data.